Bibliographic citations
Chavez, (2024). Eficacia del Rituximab en pacientes con enfermedad pulmonar intersticial asociada a enfermedad del tejido conectivo: una revisión sistemática y metaanálisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/49072
Chavez, Eficacia del Rituximab en pacientes con enfermedad pulmonar intersticial asociada a enfermedad del tejido conectivo: una revisión sistemática y metaanálisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2024. https://hdl.handle.net/20.500.12759/49072
@mastersthesis{renati/1344584,
title = "Eficacia del Rituximab en pacientes con enfermedad pulmonar intersticial asociada a enfermedad del tejido conectivo: una revisión sistemática y metaanálisis",
author = "Chavez Velasquez Ana Liz",
publisher = "Universidad Privada Antenor Orrego",
year = "2024"
}
To evaluate whether Rituximab is safer and more effective in improving lung function and reducing mortality in patients with connective tissue disease-associated interstitial lung disease compared to standard treatment or placebo. Methods: A systematic literature review was conducted following the PRISMA 2020 guidelines. Randomized clinical trials comparing rituximab with placebo or standard treatment in patients with connective tissue disease-associated interstitial lung disease were included. The risk of bias was assessed using the Cochrane Collaboration's Risk of Bias tool (ROB2). Data synthesis and meta-analysis were performed to assess forced vital capacity, carbon monoxide diffusion capacity, adverse effects, and mortality. Results: Five clinical trials that met the inclusion criteria were included. The meta-analysis showed that rituximab significantly improved final forced vital capacity compared to placebo/conventional treatment (MD = 3.62, 95% CI [3.21-4.03], p < 0.001). However, there was no significant difference in carbon monoxide diffusion capacity between the groups (MD = 5.77, 95% CI [-3.18-12.69], p = 0.10). Regarding adverse effects, there was a trend toward lower incidence with rituximab, although it was not statistically significant (RR = 0.57, 95% CI [0.26- 1.26], p = 0.17). Mortality showed no significant differences between the groups (RR = 1.96, 95% CI [0.70-5.51], p = 0.20). Conclusion: Rituximab appears to improve lung function in patients with connective tissue disease-associated interstitial lung disease, but it does not show significant benefits in carbon monoxide diffusion capacity or mortality. Although it suggests a trend toward lower incidence of adverse effects, further studies are needed to confirm these findings
This item is licensed under a Creative Commons License